If approved, Ofev would be the first approved treatment for children and adolescents with fibrosing interstitial lung disease. A decision is expected in the fourth quarter of this year.
The FDA has accepted Boehringer Ingelheim’s supplemental new drug application (sNDA) for Ofev (nintedanib), to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease (ILD). A decision is expected in the fourth quarter of this year.
Interstitial lung disease is rare condition that includes more than 200 disorders, with about 30 disorders that effect children. There are less than 10,000 estimated cases in the United States in children, according to the Children’s Interstitial Lung Disease Foundation. Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred, making it difficult to breath.
Ofev is a tyrosine kinase inhibitor that works by inhibiting pathways involved in pulmonary fibrosis. It is currently approved to treat adults with idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung disease and interstitial lung disease associated with systemic sclerosis.
The cost is about $12,496 for a supply of 60 capsules. A spokesperson said the price is similar to other therapies for rare/orphan diseases approved by the FDA. Boehringer Ingelheim offers a number of programs designed to support patients, including copay assistance for eligible patients and a patient support program.
For the children's indication, dosing would be weight-based, and the spokesperson would not comment on the price for a children's dose.
“With a long and complicated journey to diagnosis and no approved therapies, childhood interstitial lung diseases can place a significant burden on patients and their families,” Robin Deterding, M.D., director of the Breathing Institute, Children’s Hospital Colorado, said in a press release. “If approved, Ofev would be the first and only approved treatment for children and adolescents aged 6 to 17 years old with fibrosing interstitial lung disease, representing an important step forward for these patients.”
The sNDA is based on results from the InPedILD phase 3 trial, which evaluated dose-exposure and safety of Ofev on top of standard of care. In children and adolescents with fibrosing ILD, a weight-based dosing regimen resulted in exposure of Ofev similar to adults and with a similar safety profile. The most common adverse event associated with treatment was diarrhea. The complete results were published last year in the European Respiratory Journal (ERJ) and presented at the European Respiratory Society (ERS) International Congress in September 2022.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen